Lawrence C. Fritz, Ph.D.

Who is Lawrence C. Fritz, Ph.D.?

Lawrence C. Fritz joined Anadys as President and Chief Executive

Officer and a member of the Board of Directors on November 20, 2006.

Previously, he founded and developed several successful biotechnology

companies. He founded Conforma Therapeutics and served as its President

and CEO from inception in 1999 through its acquisition by Biogen Idec

in 2006. Conforma pioneered a new approach to cancer therapy,

developing drugs that induce tumor cells to degrade their deregulated

signaling proteins. Dr. Fritz is also a founder and Director of

Cabrellis Pharmaceuticals, a specialty pharma cancer company spun-out

from Conforma in conjunction with Biogen Idec's acquisition. Prior to

Conforma, Dr. Fritz co-founded both Athena Neurosciences, now

wholly-owned by Elan Corporation, and Idun Pharmaceuticals,

subsequently acquired by Pfizer. As Vice President of Research at

Athena, his work led to the clinical development of products for

multiple sclerosis, Alzheimer's disease, and neuromuscular disorders.

While Executive Vice President, Research at Idun, he led RD teams

that pioneered pharmaceutical applications in the field of programmed

cell death, or apoptosis. These efforts led to new approaches to the

treatment of hepatitis C, inflammation, and cancer. Dr. Fritz holds an

A.B. Degree in Biochemical Sciences from Harvard, a M.Sc. Degree in

Physiology from University College London, and a Ph.D. in Biophysics

from The Rockefeller University.